Do You Need a Mammogram Before HRT? Who Requires One
Do you need a mammogram before HRT?
The U.S. screening guidance we reviewed does not set a fresh mammogram as a universal condition before starting menopause hormone therapy. What does apply is breast screening for your age and risk, the screening advice in your medication's label, and your provider's prescribing requirements. Those three layers are why one doctor says "you need one first" and another accepts your existing report.
If you've heard both answers and felt a little crazy, you're not. You've been hearing different layers of rules. Here they are side by side.
The three kinds of "mammogram rules," side by side
| Layer | Who sets it | What it says (paraphrased) | Is it a "before you start" requirement? | Source (checked Oct 14, 2026) |
|---|---|---|---|---|
| Screening guidelines | U.S. Preventive Services Task Force (USPSTF) | Mammogram every 2 years for women 40 to 74 | Not a universal pre-start test; follow the applicable screening plan, including during HRT | USPSTF, final 2024 |
| American College of Obstetricians and Gynecologists (ACOG) | Start at 40 if at average risk; screen every 1 or 2 years, decided with your clinician | No | ACOG, Oct 10, 2024 | |
| American Cancer Society (ACS) | Ages 40–44 may screen yearly; 45–54 yearly; 55+ every 1 or 2 years | No | ACS, revised Jul 23, 2026 | |
| The Menopause Society | Its position statement recommends regular breast surveillance under current screening guidelines, including for women using HRT | Not a universal fresh pre-start scan | 2022 position statement, printed pp. 781–782 | |
| FDA drug labeling: Bijuva example | FDA-approved product labeling | Clinicians should assess breast cancer risk and keep up surveillance such as breast exams and mammograms. Bijuva's patient leaflet advises a yearly breast exam and mammogram unless your provider says otherwise | Not a universal pre-start rule for all HRT. Check the exact drug's label with your prescriber | Bijuva label, revised 2/2026 |
| Provider policies | Each online clinic | Ranges from "yes, before a prescription" (Elektra) to "required for refills" (Alloy) to nothing published (Gala, Winona) | Sometimes. It depends on who prescribes | See the provider table below |
One more thing worth knowing. Rules differ by country. A 2025 policy brief from the European Code Against Cancer calls for a baseline mammogram before HRT when a woman hasn't had one in the past year. That is a European policy recommendation, not a U.S. prescribing rule. If you live outside the U.S., follow your own country's screening program and prescriber.
Our take, labeled as opinion: if you're due under the screening plan you and your clinician use, getting it booked is worth doing anyway, HRT or not. Just don't let a scheduling gap turn into months of untreated hot flashes and lost sleep while nobody tells you what's actually required.
Start here: what's your mammogram situation?
Two questions settle most of this: when was your last screening mammogram, and is anything about your breasts new or unfinished? Find your row below. It tells you what the situation means and the most useful next step. It does not clear you for treatment. Only a clinician who has your history can do that.
A quick self-check to think through—no answers need to be entered on this page:
- When was your last screening mammogram? Within 12 months / 1–2 years ago / More than 2 years ago or never / Not sure / I'm under 40
- Have you noticed any new breast change: a lump, nipple discharge, skin dimpling, or pain in one spot?
- Is any earlier imaging still unfinished, such as a callback, extra views, an ultrasound or a biopsy?
- Have you had breast cancer or another estrogen-sensitive cancer?
If you answered yes to 2, 3 or 4, skip straight to When a mammogram, or more, has to come first.
Your situation, what it means, and what to do next
| Your situation | What it means | Next useful step | Question to ask |
|---|---|---|---|
| Screening within the past 12 months, normal result, no new breast change | You have a recent report to share; the prescriber still checks its findings, any follow-up and your history | Have the date, facility name and report ready for intake | "Will this report meet your requirement?" |
| Last screening 12–24 months ago | Before 24 months, this is within USPSTF's two-year interval for ages 40–74 in its covered population. It may be due sooner under an annual or special follow-up plan; ACOG allows an agreed one- or two-year interval | Ask the provider which window it uses before you pay | "Do you need a report from the past year, or will 18 months do?" |
| More than 2 years ago, or never (age 40–74, no special follow-up plan) | You're beyond USPSTF's routine screening interval, HRT or not. That's a screening task, not proof that HRT is off the table | Arrange routine screening; tell your clinician the date | "Does my result need to be back before you decide on treatment?" |
| Under 40, average risk, no symptoms | Routine screening usually starts at 40, so age alone doesn't create a pre-HRT mammogram rule | Ask what specific factor, if any, is behind a request for imaging | "Is this about my history or your clinic's policy?" |
| New lump, nipple discharge, skin change or new persistent pain in one spot | This needs clinical assessment; your clinician decides whether diagnostic imaging is needed | See a clinician in person and describe the change when you book | "Do I need diagnostic imaging rather than a screening mammogram?" |
| A callback, extra imaging or biopsy is still pending | A finished screening visit isn't the same as a finished evaluation | Contact the clinician or breast center managing the follow-up | "What's still open, and who will share the result with my HRT prescriber?" |
| Your report recommends a short-interval follow-up (often 6 months) | That plan replaces the generic yearly or two-yearly schedule | Share the exact recommendation with your prescriber | "How does this follow-up plan affect timing?" |
| Personal history of breast or another estrogen-sensitive cancer | Systemic HRT is generally not advised after breast cancer; the cancer type and treatment history matter for other cancers | Start with your oncology team | "Which menopause options fit my history?" |
| BRCA gene change, past chest radiation or another clinician-identified high-risk condition | Routine screening guidance may not apply | Ask your clinician for your specific screening plan | "Which screening plan applies before and during HRT?" |
| Family history or dense breasts on your report | These affect risk, but do not automatically place you outside USPSTF's covered population | Discuss the full history and report; follow any existing special plan | "Does my overall risk change my screening plan?" |
| Age 75 or older | USPSTF finds the evidence insufficient for a universal recommendation; ACS considers health and life expectancy | Discuss whether and how to continue screening | "What screening makes sense for me now?" |
Three checks before you book anything new
Before you pay for a new appointment or a new service, check three things. Do you already have a report? Is any follow-up unfinished? Have you asked your current prescriber what they need? Plenty of women don't need a new provider at all. They need one email to the clinician they already trust. You'll find a ready-to-send message further down this page.
Which online HRT providers require a mammogram?
Of the seven online menopause services we checked on October 14, 2026, Elektra Health says yes before a prescription, and Alloy requires an updated mammogram for recurring prescriptions. PlushCare says its physicians may ask for one, and Evernow's older published policy asks for one every two years. Midi describes help staying current, while no mammogram requirement was found on the Winona and Gala pages we reviewed. Those last two still review your health history and may ask during intake.
This comparison separates the published rules from the questions you still need to ask before paying.
Published mammogram policies, checked October 14, 2026
| Provider | What its public page says about mammograms | Applies to | How you pay | Published visit or plan price | Source |
|---|---|---|---|---|---|
| Gala Health (affiliate) | No mammogram requirement found on the HRT pages reviewed. Gala says a clinician reviews your history before deciding whether to prescribe | Not published; confirm in intake | Cash-pay; no insurance; HSA/FSA accepted | Pills $69/mo, patches $99/mo (one page says billed every 12 weeks; see the Gala section) | Gala hormone health, Gala HRT offer |
| Alloy | An updated mammogram is required for a recurring HRT prescription. Without one, the doctor may allow a one-time fill | Refills (and possibly the first fill) | See does Alloy take insurance | See Alloy cost | Alloy Help Center |
| Elektra Health | Answers "Yes" to needing a mammogram before a hormone therapy prescription, and stresses yearly mammograms while on treatment | Before the first prescription | Insurance (including Medicare and several commercial plans) or cash | Cash: $249 first visit, $149 follow-ups; check state and plan | Elektra FAQ |
| PlushCare | A physician may ask for a mammogram from the past year, or ask you to get one before starting | Case by case | See our review | See PlushCare HRT review | PlushCare HRT page (updated 11/25/2025) |
| Evernow | Requires mammograms every two years "for those for whom this is applicable" | Ongoing | See does Evernow take insurance | See Evernow cost | Evernow (page dated May 2022) |
| Midi Health | Its Chicago FAQ says clinicians help keep Paps and mammograms current, direct needed testing to a local facility and review results | Care coordination, not a stated gate | In-network with most PPO plans; self-pay option | Self-pay $250 first visit, $150 return visit | Midi pricing, Midi FAQ |
| Winona (affiliate) | No mammogram requirement found on its FAQ or mammogram article; FAQ says no bloodwork or hormone testing is required | Not published; confirm in intake | See does Winona take insurance | See Winona HRT cost | Winona FAQ |
How to read this table
- "Not published" is not "not required." Gala's and Winona's clinicians can still ask about screening during their health-history review.
- Alloy's one-time fill isn't guaranteed. Alloy says it's up to the prescribing physician. Ask the prescriber when screening must be completed; a possible one-time fill is not permission to postpone follow-up.
- Elektra is the clearest "before" rule we found. If you're current on screening and need insurance, including Medicare, that clarity can be a plus. If you're overdue, expect to schedule imaging first.
- Evernow's page is from 2022. We list it because it's still live and states a rule, but confirm it with Evernow before you rely on it.
- Midi is the "help me get it done" option. If you'd like a clinician to arrange screening alongside your menopause care, and you want insurance to pay for visits, that's Midi's published approach.
Ready to compare cash-pay care? If you have no new breast changes or unfinished follow-up and your history does not call for specialist review, Gala is our featured option for online review, shipping and ongoing support. Confirm that it serves your age and state, accepts your screening records and offers the medication you need. Its offer says you're charged if approved, but the linked general refund policy describes a charge when intake is completed. Ask which timing applies before submitting payment details. Tell the clinician your last mammogram date.
Affiliate link. A clinician decides whether treatment is right for you; a prescription isn't guaranteed.
How recent does your mammogram need to be?
For routine screening, USPSTF recommends every two years at ages 40–74, while ACOG recommends an agreed one- or two-year interval starting at 40. ACS uses age bands, and special-risk or follow-up plans can differ. Provider requirements don't always match. "Up to date" can mean the past 12 months at one clinic and the past 24 at another. Ask the provider you choose which window it uses before you pay.
Screening schedules versus prescribing rules
| Source | Interval | Ages | What it means for you |
|---|---|---|---|
| USPSTF | Every 2 years | 40–74, in the population covered by its guidance | An 18-month-old scan is within this interval, unless a separate follow-up plan applies |
| ACOG | Every 1 or 2 years, decided with your clinician | Starting at 40 | "Current" depends on the schedule you and your clinician agreed on |
| ACS (average risk) | 40–44 optional yearly; 45–54 yearly; 55+ every 1 or 2 years | 40+; continue while in good health with 10+ years of expected life | At 45–54, ACS expects yearly screening |
| Medicare Part B (coverage, not a prescribing rule) | Covers one screening every 12 months | 40+ | Ask the imaging center to confirm your next covered date |
| HealthCare.gov (Marketplace and many other plans) | Every 1–2 years | 40+ | Usually $0 in-network as preventive care |
| FDA patient leaflet (Bijuva example) | Yearly, unless your provider says otherwise | Women using Bijuva | This is Bijuva's instruction, not a verified rule for every HRT product |
| Alloy | An "updated" mammogram for recurring HRT | No exact interval in the cited policy | Ask how recent it must be; the page does not define 12 months |
| PlushCare | A physician may request a report from the past year or new imaging | Case by case | A 12-month report request is possible, not universal |
| Evernow (2022 page) | Every 2 years | Where applicable | 24-month window, if still current |
| USPSTF, age 75+ | Evidence insufficient to recommend for or against | 75+ | A personal decision with your clinician |
ACS defines "average risk" as no personal history of breast cancer, no strong family history, no known risk gene such as BRCA, and no chest radiation before age 30. If any of those apply to you, the age table above may not fit you at all.
The right online menopause care isn't the same for every woman — it depends on your symptoms, what you've already tried, your age, your state and your health history. Some situations belong with an in-person clinician first. Use The HRT Index's Find My HRT Path tool to explore a featured care option for your situation — and to flag when online care isn't the right starting point — before your first consult. It's free, takes about 60 seconds and doesn't ask for your email. It won't tell you whether you need a mammogram or whether HRT is safe for you. That's still your clinician's call.
Have a new breast change or unfinished imaging? Don't use the tool to decide whether it can wait. Contact a clinician first.
Worked example: the same mammogram, different answers
Hypothetical example, not a patient story. Dana is 51. Her last screening mammogram was 18 months ago and was normal. She has no new breast changes, no unfinished follow-up and no high-risk condition requiring a separate plan.
- USPSTF: within the two-year interval. Under that schedule, screening is due at 24 months.
- ACS: at 45–54, ACS expects yearly screening, so she's about six months overdue on that schedule.
- A clinic that wants a report from the past year: it may ask for a new mammogram before prescribing, or before refills.
- A clinic with no published rule: she still needs to ask whether that report is enough. Silence does not settle the requirement.
So the right question for Dana isn't "Which website says yes?" It's "Which schedule are we using, and does your clinic need anything more?"
When a mammogram, or more, has to come first
Get checked before starting HRT if you have a new breast lump, nipple discharge, skin change or new persistent pain in one spot. A clinician should assess the change and decide whether diagnostic imaging is needed; don't treat it as a routine-screening question. The same goes if earlier imaging is still unfinished. If you've had breast cancer, systemic HRT is generally not used, so that conversation belongs with your oncology team.
This is the part of the page that matters most, so we'll keep it plain.
If you've noticed a new breast change
A screening mammogram looks for problems in women who have no symptoms. A diagnostic mammogram investigates something specific, like a lump or a spot on an earlier scan. Diagnostic imaging takes more views, according to the National Cancer Institute, and it's usually billed differently.
If something feels new or different, call your doctor or a breast center. Describe the change when you book. Don't book it as routine screening to save money. That can mean the wrong test, and the bill may change anyway once the change is noted.
A normal mammogram from last year doesn't cover a change you've noticed since. And a change doesn't mean cancer. Most turn out to be harmless. It just needs to be checked by someone who can examine you.
If imaging is still unfinished: reading your report
Mammogram results are reported with a scoring system called BI-RADS (Breast Imaging Reporting and Data System). It runs from 0 to 6. Your report will usually name the category and the next step. Here's what each category generally means, based on the American Cancer Society's guide:
| BI-RADS | What it means | Typical next step | What your HRT prescriber needs to know |
|---|---|---|---|
| 0 | Incomplete; more images or comparison with old films needed | Additional imaging or comparison with prior films, as requested | The evaluation is unfinished; share what remains and who is managing it |
| 1 | Negative; nothing new or abnormal | Routine screening | Share the report and mention any new symptom since the scan |
| 2 | Benign (not cancer) finding, described for the record | Routine screening | Share the report and its recommendation |
| 3 | Probably benign; very low chance of cancer | Repeat imaging, often in 6 to 12 months | Share the follow-up plan with your prescriber |
| 4 | Suspicious; biopsy should be considered | Biopsy as recommended | Tell the prescriber that further evaluation is pending |
| 5 | Highly suggestive of cancer | Biopsy | Coordinate the breast-team evaluation and menopause discussion |
| 6 | Cancer already confirmed by biopsy | Cancer care | A specialist conversation |
The last column is our plain-language guide, not a clearance chart. It's there so you know which conversation comes next. A callback doesn't mean you have cancer. The CDC notes that an abnormal result often just means more pictures are needed. Your HRT prescriber should still know the evaluation isn't finished.
If you've had breast cancer
The FDA labels for systemic hormone therapy list breast cancer, or a history of it, as a reason not to use the drug. The Menopause Society says women who have had breast cancer generally shouldn't use hormone therapy.
Low-dose vaginal estrogen is a separate question. The Menopause Society's 2022 position statement says it can be considered for vaginal symptoms after nonhormone treatments have been tried, in consultation with an oncologist. That's a decision to make with your cancer team, not a workaround. Read more in our guide to vaginal estrogen after breast cancer.
The tool's published how-it-works page says a breast-cancer history can lead to a cautious clinician-review option, including consideration of non-hormonal care. That does not replace the conversation with your oncology team, and it never decides that HRT is right for you.
If you're at higher risk or have dense breasts
A BRCA gene change, a strong family history or a history of chest radiation can mean you need a different screening plan, sometimes including MRI. Dense breasts have more glandular and fibrous tissue and less fat. Nearly half of women 40 and older who get mammograms have dense breasts, according to NCI. Density makes mammograms harder to read, and it's also a risk factor of its own.
Whether women with dense breasts should get extra ultrasound or MRI screening is unsettled. The USPSTF says the evidence isn't strong enough to recommend for or against it. That's a conversation for your clinician, using your full report and history. See HRT when breast cancer runs in your family.
Other reasons to start in person (not breast-related)
The Menopause Society lists other situations where hormone therapy generally isn't a good choice: uterine cancer, unexplained vaginal bleeding, liver disease, a history of blood clots, and cardiovascular disease. These need review by a clinician who knows the condition; an exam or specialist visit may be needed before treatment. A routine online intake is not a substitute for that review. If you're bleeding unexpectedly, read bleeding after starting HRT and call your clinician.
Can you start HRT while you wait for your mammogram?
That's your prescriber's decision, made with your history in front of them. Published policies differ: Alloy says a clinician may allow a one-time fill without a recent mammogram, while Elektra says a mammogram is needed before a hormone-therapy prescription. A booked routine screen and unfinished diagnostic follow-up are different situations.
What we can tell you is how to make the conversation quick:
- Say what kind of gap it is. "My routine screening is booked for the 22nd" is very different from "I was called back and haven't gone."
- Ask what can happen now. Even if a prescription waits, a visit can still cover your symptoms, your options and what a plan would look like.
- Expect provider differences. Elektra says a mammogram comes before a prescription. Alloy may allow a one-time fill. Gala and Winona publish no rule.
A normal mammogram doesn't guarantee you'll never get breast cancer. A missing mammogram isn't a diagnosis either. It's simply information your clinician doesn't have yet.
Booked your routine screening and want to explore cash-pay care? You can review Gala's assessment and give the clinician your appointment date. Ask whether it needs the result before prescribing and whether any charge occurs before review. Gala's public pages do not settle those HRT-specific requirements.
Affiliate link. A prescription isn't guaranteed.
Does the type of HRT change the answer?
Yes, the type changes the conversation. Systemic hormone therapy sends hormones into your bloodstream to treat whole-body symptoms like hot flashes. Low-dose vaginal estrogen treats vaginal and urinary symptoms with very little absorbed into the blood. Your age- and risk-based screening plan still applies. Some provider rules may treat the two differently, so ask about the exact product.
The Menopause Society describes systemic therapy as pills, patches, sprays, gels or a vaginal ring that deliver hormones throughout the body. Low-dose vaginal estrogen is placed in the vagina, and very little reaches the bloodstream, so its risks are far lower.
Bring the exact product, not just "HRT"
| Treatment you're discussing | What kind it is | Uterus protection? | Question for your prescriber |
|---|---|---|---|
| Estradiol pill, patch, gel or spray | Systemic | If you have a uterus, you also need a progestogen | "What breast-screening rule applies to this prescription?" |
| Systemic vaginal ring (higher-dose) | Systemic | Same as above | "Is this ring systemic or local?" |
| Low-dose vaginal estradiol cream, tablet or ring | Local | The Menopause Society says a progestogen isn't required (long-term trial data are limited) | "Does your mammogram rule apply to vaginal-only treatment?" |
| Progesterone (often oral micronized progesterone) | Protects the uterine lining when you take systemic estrogen | — | "Which progesterone form is this, and why?" |
| Compounded hormone product | Not FDA-approved as a finished drug | Depends on the product | "What exact product would I get, and why compounded?" |
| Testosterone for women | Use of an FDA-approved testosterone drug in women is off-label in the U.S.; compounded products are not FDA-approved. Testosterone is Schedule III | — | "What monitoring and screening do you want while I'm on it?" |
A progestogen is progesterone or a similar hormone. If you still have a uterus and take systemic estradiol, you need a suitable progestogen regimen to protect the uterine lining. The Menopause Society says this is why women with a uterus use combined therapy.
Words like "bioidentical" or "cream" don't tell you whether a product is FDA-approved or whether it's systemic or local. The FDA explains that compounded drugs are not FDA-approved. Ask for the product name. Our guide to compounded HRT safety explains the difference.
What changed in 2026, and what didn't
On February 12, 2026, the FDA approved label changes for the first six menopause hormone therapy products. The changes remove heart disease, breast cancer and probable dementia from the boxed warning, the FDA's most prominent safety warning. The updated Bijuva label still tells clinicians to assess breast cancer risk and keep up surveillance such as breast exams and mammograms.
Here's what that looks like in Bijuva's original 2018 label compared with its February 2026 revision, checked October 14, 2026:
| Bijuva original label (2018) | Bijuva revised label (February 2026) | |
|---|---|---|
| Boxed warning mentions breast cancer | Yes | No |
| Breast cancer listed as a reason not to use the drug | Yes | Still yes |
| Clinicians told to watch for breast cancer with exams and mammography | Yes | Still yes |
| Patient leaflet: yearly breast exam and mammogram unless your provider says otherwise | Yes | Still yes (Bijuva example) |
The FDA announced an initial six updated products on February 12, 2026: Prometrium, Divigel, Cenestin, Enjuvia, Estring and Bijuva. Those six also appear on the FDA's linked list at this check. Its February announcement said 29 companies had submitted proposed changes; that is not a verified October count of completed updates.
Sources: FDA announcement, FDA list of updated labels, Bijuva revised label, Bijuva original label.
Our take: the change is real good news for access. In announcing it, the FDA pointed to randomized studies showing that women who start HRT within 10 years of menopause onset, generally before 60, had fewer deaths from any cause and fewer fractures. It does not mean breast screening is unnecessary, and it doesn't make HRT risk-free. For the numbers by type, read HRT and breast cancer risk and is HRT safe in 2026.
Does HRT affect your mammogram?
It can. Hormone therapy is linked to denser-looking breast tissue, and the label for one combined estrogen-plus-progestogen product notes more abnormal mammograms that need a second look. That's a reason to keep screening and tell the technologist you're on HRT. It isn't a reason to skip screening or to stop HRT on your own before your appointment.
Density, callbacks and your report
- NCI lists menopausal hormone therapy among the factors linked with higher breast density.
- On a mammogram, dense tissue and some abnormal changes both look white, so density makes mammograms harder to read.
- Since September 10, 2024, mammography facilities subject to the federal MQSA rules must include breast-density information in reports and patient summaries, under an FDA rule. Look for that line, then bring it to your HRT consult.
- Mammograms work best when they can be compared with earlier ones, the CDC notes. Going back to the same facility, or bringing old images, helps.
Should you stop HRT before your mammogram?
Don't change your treatment because of this page. One randomized trial tested this question directly. Researchers at a Washington health plan randomly assigned 1,704 women who were already using HRT; the trial was designed for women ages 45 to 80. Some kept going, some paused for one month, and some paused for two months before their screening mammogram (Buist et al., Annals of Internal Medicine, 2009, Table 2).
| Group | Women analyzed | Recalled for more imaging |
|---|---|---|
| Kept taking HRT | 542 | 11.3% |
| Paused 1 month | 478 | 12.3% |
| Paused 2 months | 451 | 9.8% |
The pause made only small changes in density, and the trial found no statistically significant difference in recall rates. Women in the pause groups reported more menopause symptoms, including hot flashes, night sweats and sleep problems. The authors concluded there was no evidence to support a short break before mammography. The study looked at women already on HRT, not at whether to start. Ask your prescriber and imaging center for their instructions.
What does a mammogram cost, and how do you book one fast?
A routine screening mammogram is often $0. Medicare Part B covers one every 12 months for women 40 and older with no cost to you when the provider accepts Medicare's approved amount. HealthCare.gov says Marketplace plans and many other plans cover screening every one to two years from 40 without a copay when you use an in-network provider. A diagnostic mammogram, for a symptom or follow-up, can have different coverage and cost-sharing; ask about the actual order.
Screening versus diagnostic: what you'll likely pay
| Screening mammogram | Diagnostic mammogram | |
|---|---|---|
| Who it's for | No symptoms; routine check | A symptom, or a follow-up of an earlier finding |
| Original Medicare | $0 once every 12 months (40+) if the provider accepts assignment | 20% of the approved amount after the Part B deductible |
| Marketplace and many other plans | Generally $0 in-network every 1–2 years (40+); coverage may vary | Depends on the plan and applicable diagnostic-imaging coverage; ask for an estimate |
| No insurance, low income | May be free or low-cost through the CDC's program (eligibility rules apply) | Program also funds diagnostic services for eligible women |
| Sources | Medicare.gov, HealthCare.gov, CDC NBCCEDP | Same |
"Generally $0" is not a promise. HealthCare.gov says coverage may vary, and older "grandfathered" plans can follow different rules. Before your appointment, ask the questions below.
Five cost questions to ask when you book:
- "Is this ordered as a screening or a diagnostic mammogram?"
- "Are both the imaging center and the radiologist in my network?"
- "What will I owe today, and could extra views or an ultrasound be billed separately?"
- "Do I need an order from a clinician, or can I book a screening myself?"
- "Is 3D mammography (tomosynthesis) billed differently under my plan?"
No insurance? The CDC's National Breast and Cervical Cancer Early Detection Program helps women with low incomes who lack adequate insurance get screening and diagnostic services. Use the CDC's screening-program locator to check whether you qualify in your state.
Book it this week: a checklist
- Find your last date. Check your patient portal, call the imaging center you used, or ask your OB-GYN's office.
- Pick the right appointment. No symptoms and no pending follow-up usually means routine screening. A new change or unfinished finding means telling the clinician and scheduler, so they can arrange the right assessment.
- Ask about an order. Some centers let you book a screening yourself. Others need an order from a clinician.
- Time it kindly. If you still have periods, the CDC suggests avoiding the week before and during your period, when breasts can be tender.
- On the day, skip deodorant, perfume and powder. They can show up as white spots on the X-ray.
- Tell the technologist you're on HRT, or about to start.
- Expect pressure. The CDC says most women find it uncomfortable and some find it painful, but it lasts only moments.
- Save the report and note the density line and the BI-RADS category. Ask the facility when and how results will arrive.
Copy and send: the questions for your clinician
The fastest way through this is usually one clear message to the clinician who will prescribe. Copy the message below, fill in the brackets, and send it through your provider's secure patient portal. Don't post health details in public comments or reviews.
I'm considering menopause hormone therapy. My last mammogram was [date / I haven't had one / I'm not sure]. The report recommended [routine screening / follow-up on (date) / I need to get the report]. Before I book or pay, could you tell me:
- Do you need my existing report, or new imaging?
- How recent does it need to be?
- Does the result need to be reviewed before you prescribe?
- Does this apply to the exact treatment we'd discuss (for example, a patch, a pill, or vaginal-only estrogen)?
- Who would order any imaging, and can we talk about symptom-care options while I wait?
Tell your clinician separately about any new breast change or unfinished follow-up. Don't fold it into a routine records question.
[BUTTON: Copy these questions — copies the message above to the clipboard; no form, no email capture]
Records checklist
| Have this ready | Why it helps |
|---|---|
| Date and facility of your last mammogram | Lets the clinic request the actual report |
| The written report, including BI-RADS and density lines | Ties the next step to what the radiologist actually said |
| Status of any callback, ultrasound or biopsy | Keeps "scan done" from being mistaken for "evaluation finished" |
| Current and proposed medication names | Keeps the rule product-specific |
| Relevant personal and family history | Helps your clinician judge risk and screening plan |
| Who receives your results and who reviews them | Avoids results falling between two offices |
| Billing and cancellation answers, in writing | Prevents surprises if timing slips |
These are prompts for your own records. You do not need to upload medical records to use this checklist.
Which care route fits you?
For readers considering cash-pay online care after the screening question is clear, Gala Health is our featured option—subject to its clinician's review, age/state availability, medication fit and written terms. For commercial insurance, check Midi or Elektra against your exact plan. Elektra lists Medicare in selected states; Midi does not bill Medicare. If the care route is still unclear, The HRT Index's Find My HRT Path tool can help you explore a featured option in about a minute.
Gala Health HRT: our featured cash-pay option
Last verified October 2026 (pages checked October 14, 2026). This is a documentation review of Gala's public pages, not a test of its care.
| What you'd want to know | What Gala's pages say | Still to confirm |
|---|---|---|
| Mammogram rule | None published on its HRT pages | Whether intake asks for a date or report |
| Who reviews you | A U.S.-licensed provider reviews your assessment, usually within 24 hours, Gala says; some states require a short video visit | Your assigned clinician, license and actual response time; these were not independently tested |
| Medications | Estradiol pill or patch; progesterone (oral capsule on its plan page; its FAQ also mentions vaginal); vaginal estradiol; non-hormonal options. One HRT page says FDA-approved forms; the other carries a compounded-drug notice | Exact finished product, maker, FDA-approved versus compounded status, and whether the prescribed route/use is off-label |
| Price | Pills $69/mo; patches $99/mo | The exact plan shown before you pay |
| Billing | One Gala offer page says pills are billed $207 every 12 weeks and patches $297 every 12 weeks; another describes $69 a month flat | The amount due at approval and how often you're billed |
| When you're charged | The HRT offer says a charge follows approval and no charge applies if the state is not served. Its linked general refund policy instead describes charging at intake completion | Which timing and refund terms govern your HRT checkout; we did not submit intake or payment details |
| What's included | Gala advertises provider review, prescribed treatment, free shipping, ongoing messaging and dose adjustments; no separate membership fee | Whether the selected price covers every medication, including a progestogen when needed |
| Labs and imaging | HRT pages mention lab-guided care but do not establish a complete HRT lab-price schedule or mammogram inclusion | Required tests, who orders them and any separate charge; unknown is not $0 |
| Insurance | Doesn't bill insurance; HSA/FSA accepted | — |
| States and ages | "Most U.S. states"; confirmed during the assessment. No published HRT age range | Whether it serves you |
| Cancellation | Cancel or pause anytime from your account. Gala's general refund policy asks for 72 hours' notice before your billing date | Whether that policy governs HRT plans |
| Refunds | The linked general policy restricts cancellation refunds except for medical disqualification; it includes GLP-1/weight-loss wording | Whether it governs HRT, what happens during an imaging delay, and which fees are refundable |
| Commitment and continuity | The HRT offer says no contract; the linked general policy describes service through the paid cycle after cancellation | Minimum prepaid period for your selected plan, last covered refill/support date, and whether prescriptions can be transferred |
Source: Gala hormone health, Gala HRT offer page, Gala HRT FAQ page, Gala refund policy (Last Updated February 2026). Full details are in our Gala Health HRT review.
What it could cost: worked math from Gala's published prices
Gala's 12-week HRT offer advertises the charges below. Its other HRT landing page says $69 a month flat without the same plan detail. These are examples using the published 12-week offer, not a verified checkout quote or a complete medical-care total.
| Plan on the 12-week offer | Published charge for one 12-week cycle | Prorated value of 52 weeks at that rate—not cash paid | Cash charged within 52 weeks if billed upfront at weeks 0, 12, 24, 36 and 48 |
|---|---|---|---|
| Pills, advertised as $69/mo | $207 | $897 | $1,035 in five charges, buying 60 weeks |
| Patches, advertised as $99/mo | $297 | $1,287 | $1,485 in five charges, buying 60 weeks |
How we got there: $207 ÷ 12 × 52 = $897 of prorated service, while five actual $207 charges total $1,035. For patches, $297 ÷ 12 × 52 = $1,287 of service, while five $297 charges total $1,485. The last upfront payment covers weeks 48–60. These examples assume unchanged prices, uninterrupted renewals and no refunds; they do not establish your first charge date.
Twelve weeks is 84 days, not three calendar months. Gala's $69 and $99 "per month" figures on that offer work out to four-week equivalents. Confirm the exact amount due now, the renewal interval and all included medicines before paying. A mammogram or lab bill is not established as included. Anything the applicable plan does not price is unknown, not zero.
Where Gala fits best:
- You want cash-pay online care. The published Find My HRT Path flow features Gala for many readers 40 and older; that is navigation placement, not Gala's verified age-eligibility rule.
- You have no new breast changes, no unfinished imaging and no history of breast cancer.
- Your screening records or appointment are ready to discuss, and you will confirm what Gala needs before prescribing.
- You prefer an advertised bundled price and are willing to confirm the billing cycle, included medicines and any testing costs.
- You want ongoing messaging and dose adjustments included.
Where it doesn't:
- You need insurance to pay for care. Gala doesn't bill insurance.
- You want the provider to order or arrange your mammogram. Midi's published approach fits better.
- You have a breast change, unfinished follow-up, or a history of breast cancer. Start in person.
One candid limitation: the linked refund policy still uses GLP-1/weight-loss wording, so we cannot confirm it governs HRT. If it does, it restricts cancellation refunds and requires 72 hours' notice before billing. Its intake-charge wording also conflicts with the HRT offer's approval-first wording. With a prepaid 12-week cycle, those details matter. Ask which written terms apply, what is charged today and what happens if imaging delays a prescription before you submit payment details.
On its own site, a Gala patient named Allison, 51, says "Gala's provider walked me through the options." That's a testimonial Gala published. We haven't verified it, and it isn't evidence of typical results.
Ready to compare cash-pay care with your mammogram date in hand? Gala says its assessment takes about five minutes and a licensed clinician reviews your history. Review the HRT plan, then confirm the screening requirement, exact medicine, charge timing and renewal terms before you pay.
Affiliate link. A clinician decides whether treatment is appropriate; a prescription isn't guaranteed.
Need insurance to pay? Midi Health or Elektra Health
If your plan should be paying, start with your coverage before comparing cash prices.
| Midi Health | Elektra Health | |
|---|---|---|
| Mammogram policy | Clinicians help you stay current and direct you to a facility | Says yes, before a hormone therapy prescription |
| Insurance | In-network with most PPO plans; check your state and plan on its site | Lists commercial plans, Medicaid plans and Medicare |
| Medicare | Midi says it is out of network; Medicare patients may self-pay but cannot submit these claims to Medicare | Listed for New York, Connecticut, Massachusetts, Florida, Pennsylvania and New Jersey; confirm your exact plan and location |
| Medicaid | Not accepted | Some Medicaid plans listed |
| Self-pay visits | $250 first (30 min); $150 return (15 min) | $249 first; $149 follow-ups |
| Medication and testing costs | Not included in the visit-price comparison below; confirm pharmacy, lab and imaging charges | Not established by the visit fees; confirm pharmacy, lab and imaging charges |
| Hypothetical first year, visits only (1 first visit + 2 follow-ups, self-pay) | $250 + $150 + $150 = $550, plus medication | $249 + $149 + $149 = $547, plus medication |
| Sources | Midi pricing & insurance | Elektra FAQ |
The visit counts in that hypothetical row are ours, not the providers'. Your number of follow-ups depends on your care. Medication, testing and other required charges are outside those visit-only totals. With insurance, your cost can include a deductible, copay or coinsurance. Check the state and plan rather than assuming coverage.
More: does Midi take insurance, Elektra Health review, online HRT that accepts insurance.
Already have a clinician you trust?
You may not need a new service at all. Send them the questions above and ask whether they can handle the screening order and the HRT conversation together. Continuity of care is worth a lot.
In your late 30s?
Routine screening usually starts at 40, so age alone isn't a reason to need a mammogram first. The published Find My HRT Path flow handles this age group differently: it describes guidance-only results under 35 and a featured Winona route at 35–39. Winona publishes an HRT age range of 35–59 in supported states; its clinician still decides whether its medication options fit. A reader who needs a particular FDA-approved product should confirm the exact medicine, not infer it from an age match. Read when to start HRT in perimenopause.
Over 60, or more than 10 years past menopause?
Screening still matters, and the HRT decision itself has more to weigh. Start with can you start HRT after 60.
How mammogram rules fit The HRT Index Verification Standard
When we compare online menopause providers, we look at five things, always in this order. Here's how a mammogram policy shows up in each one.
| Pillar | What we look for on this topic |
|---|---|
| Clinical legitimacy | Does a licensed clinician review breast cancer history and other reasons not to prescribe before writing a prescription? |
| Care quality | Does the provider help you stay current on screening, with reminders, orders or a facility referral, and explain who reviews results? |
| Medication fit | Does its rule distinguish systemic HRT from low-dose vaginal estrogen, and does it name the exact product, including whether it's FDA-approved or compounded? |
| Price transparency | Is the mammogram rule published before you pay? Does imaging add a cost you'll pay elsewhere? Are billing interval and refunds clear? |
| Access | Can a missing or older mammogram block your first prescription or your refills, and what does the provider offer instead? |
We don't assign numerical provider scores in this guide. These five public pillars group the more detailed criteria on our methodology page.
Frequently asked questions
Do you need a mammogram before HRT if you're under 40?
Usually not because of age alone. Routine screening generally starts at 40 for women at average risk. If a clinician recommends imaging, ask whether it's because of your history, a symptom, or the clinic's policy.
Do you need a mammogram before vaginal estrogen?
Your regular age-based screening still applies. Low-dose vaginal estrogen puts very little hormone into your bloodstream, and some providers' rules may not cover it. Ask whether the requirement applies to vaginal-only treatment.
Can an online provider refuse HRT without a mammogram?
Yes. A prescriber may require screening or records before prescribing, even though the screening guidance reviewed here does not set a universal fresh pre-HRT scan. Elektra asks for one before prescribing, and Alloy requires an updated one for refills.
Can an ultrasound, breast exam or blood test replace a mammogram?
Not for the same purpose. A clinician chooses the right breast imaging for your situation, and a hormone blood test isn't breast imaging at all. Most women don't need hormone blood tests to start menopause HRT; ACOG advises against routine hormone testing before treatment for menopausal symptoms. See do you need blood tests for HRT.
What if you already started HRT without a mammogram?
Ask your prescriber which screening schedule applies to you and book your next screening if you're due. Starting without a fresh scan isn't automatically a mistake. Don't let it delay checking any new breast change.
Do the 2026 FDA label changes mean you don't need breast screening?
No. The FDA's February 2026 announcement concerned boxed-warning changes for an initial six products. The revised Bijuva label still calls for breast-risk assessment and surveillance, and routine screening guidance still applies.
Do you need a mammogram before testosterone?
Use of an FDA-approved testosterone drug in women is off-label in the U.S.; a compounded product is not FDA-approved. The FDA's testosterone statement describes approved use in men with specified medical conditions. It requires a prescription and is listed by the DEA as Schedule III. Your age-based breast screening still applies. Ask your prescriber what monitoring they want. See is compounded testosterone safe for women.
Does Gala require a mammogram?
Gala's public HRT pages list no mammogram requirement as of October 14, 2026. Its clinician reviews your full health history and may ask about screening. Have your last mammogram date ready.
How we researched this guide
This is editorial research by The HRT Index Editorial Team. It hasn't been reviewed by a clinician. Why we label pages this way.
We reviewed the primary medical guidance and provider documents used for this guide on October 14, 2026; older source dates and unresolved provider details are identified where they matter. Medical and regulatory statements come from FDA labeling, U.S. screening bodies, the National Cancer Institute, the CDC and The Menopause Society. Provider policies and prices come only from each provider's own public pages, and they describe only that provider. We didn't complete any intake, consult or purchase. Where a provider's pages conflict or stay silent, we say so rather than guess.
Gala Health and Winona are affiliate partners. Partner compensation affects which providers we feature and the order they appear in Find My HRT Path. It doesn't change the facts in our tables. Affiliate disclosure.
We recheck Gala's price and terms monthly and the other providers' policies quarterly, or sooner when something changes. Spot something out of date? Tell us, and we'll log the fix on our corrections page.
Still deciding where to start?
By now you know whether a mammogram is a records question, a booking task or an in-person conversation. The remaining question is which kind of care fits you. The HRT Index's Find My HRT Path tool asks about your symptoms, what you've already tried, your age, your state and your health history. Then it shows one featured care option, or a clear flag when online care isn't the right starting point. It's free, takes about a minute and doesn't ask for your email. It doesn't decide whether you need a mammogram or whether HRT is right for you. See exactly how it works.
Related guides
- HRT and breast cancer risk: the real numbers by type
- What happens at your first telehealth menopause visit
- What to expect when starting HRT
- HRT side effects, including breast tenderness
- What can delay an online HRT prescription
- Gala Health vs Alloy · Gala Health vs Midi
- Compare online menopause care
Sources
Primary-source documentation review: October 14, 2026. Provider statements describe published policies and offers, not a completed intake or checkout.
Regulatory and drug labeling
- FDA. FDA Approves Labeling Changes to Menopausal Hormone Therapy Products. February 12, 2026.
- FDA. Menopausal Hormone Therapies with Updated Prescribing Information.
- FDA. Bijuva prescribing information. Revised 2/2026; compared with the original 2018 label.
- FDA. Prometrium prescribing information. Revised 2/2026; oral product and indication checked, not evidence of Gala dispensing it.
- FDA. Understanding the Risks of Compounded Drugs.
- FDA. Class-wide labeling changes for testosterone products. February 28, 2025.
- DEA. Drug Scheduling.
- FDA. Final Rule to Amend the Mammography Quality Standards Act. Effective September 10, 2024.
Screening guidance and medical sources
- U.S. Preventive Services Task Force. Breast Cancer: Screening. 2024.
- ACOG. Should I have hormone testing before starting hormone therapy?. Published and reviewed December 2025; read during this audit.
- ACOG. ACOG Updates Recommendation on When to Begin Breast Cancer Screening Mammography. October 10, 2024.
- American Cancer Society. Breast Cancer Screening Guidelines. Revised July 23, 2026.
- American Cancer Society. Understanding Your Mammogram Report. Revised July 23, 2026.
- National Cancer Institute. Mammograms.
- National Cancer Institute. Dense Breasts: Answers to Commonly Asked Questions.
- CDC. Mammograms. Updated September 22, 2026.
- CDC. About the National Breast and Cervical Cancer Early Detection Program. Updated September 18, 2026.
- The Menopause Society. Hormone Therapy and Cancer.
- The Menopause Society. The 2022 Hormone Therapy Position Statement. Menopause, 2022.
- Buist DS, et al. Short-term hormone therapy suspension and mammography recall: a randomized trial. Annals of Internal Medicine, 2009. Full author manuscript, including Tables 2 and 5.
- European Code Against Cancer (IARC). Hormone therapy policy brief. 2025.
Coverage
- Medicare.gov. Mammograms.
- HealthCare.gov. Preventive Care Benefits for Women.
Provider pages (describe only that provider's own offer or policy)
- Alloy. Do I need a mammogram?
- Elektra Health. Frequently Asked Questions.
- Evernow. Mammography and Menopausal Health. May 2022.
- PlushCare. Hormone Replacement Therapy. Updated November 25, 2025.
- Midi Health. Pricing & Insurance and location FAQ.
- Winona. FAQ and mammogram article.
- Gala Health. Hormone health, HRT offer, HRT FAQ page, Refund policy.